Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys
Identifieur interne :
003859 ( PascalFrancis/Curation );
précédent :
003858;
suivant :
003860
Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys
Auteurs : J. S. Schneider [
États-Unis] ;
A. Pope-Coleman [
États-Unis] ;
M. Van Velson [
États-Unis] ;
F. Menzaghi [
États-Unis] ;
G. K. Lloyd [
États-Unis]
Source :
-
Movement disorders [ 0885-3185 ] ; 1998.
RBID : Pascal:98-0354366
Descripteurs français
- Pascal (Inist)
- Parkinsonisme,
Lévodopa,
Chimiothérapie,
Antiparkinsonien,
Agoniste,
Récepteur nicotinique,
Acétylcholine,
Neurone,
Association médicamenteuse,
Motricité,
Psychométrie,
Traitement,
Dose efficace,
Relation dose réponse,
Singe,
Animal adulte,
Mâle,
SIB 1508Y.
- Wicri :
English descriptors
- KwdEn :
- Acetylcholine,
Adult animal,
Agonist,
Antiparkinson agent,
Chemotherapy,
Dose activity relation,
Drug combination,
Effective dose,
Levodopa,
Male,
Monkey,
Motricity,
Neuron,
Nicotinic receptor,
Parkinsonism,
Psychometrics,
Treatment.
| pA |
| A01 | 01 | 1 | | @0 0885-3185 |
|---|
| A03 | | 1 | | @0 Mov. disord. |
|---|
| A05 | | | | @2 13 |
|---|
| A06 | | | | @2 4 |
|---|
| A08 | 01 | 1 | ENG | @1 Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys |
|---|
| A11 | 01 | 1 | | @1 SCHNEIDER (J. S.) |
|---|
| A11 | 02 | 1 | | @1 POPE-COLEMAN (A.) |
|---|
| A11 | 03 | 1 | | @1 VAN VELSON (M.) |
|---|
| A11 | 04 | 1 | | @1 MENZAGHI (F.) |
|---|
| A11 | 05 | 1 | | @1 LLOYD (G. K.) |
|---|
| A14 | 01 | | | @1 Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University @2 Philadelphia, Pennsylvania @3 USA @Z 1 aut. @Z 2 aut. @Z 3 aut. |
|---|
| A14 | 02 | | | @1 SIBIA Neurosciences, Inc @2 La Jolla, California @3 USA @Z 4 aut. @Z 5 aut. |
|---|
| A20 | | | | @1 637-642 |
|---|
| A21 | | | | @1 1998 |
|---|
| A23 | 01 | | | @0 ENG |
|---|
| A43 | 01 | | | @1 INIST @2 20953 @5 354000077139450030 |
|---|
| A44 | | | | @0 0000 @1 © 1998 INIST-CNRS. All rights reserved. |
|---|
| A45 | | | | @0 28 ref. |
|---|
| A47 | 01 | 1 | | @0 98-0354366 |
|---|
| A60 | | | | @1 P |
|---|
| A61 | | | | @0 A |
|---|
| A64 | | 1 | | @0 Movement disorders |
|---|
| A66 | 01 | | | @0 USA |
|---|
| C02 | 01 | X | | @0 002B02B06 |
|---|
| C03 | 01 | X | FRE | @0 Parkinsonisme @2 NM @5 01 |
|---|
| C03 | 01 | X | ENG | @0 Parkinsonism @2 NM @5 01 |
|---|
| C03 | 01 | X | SPA | @0 Parkinson síndrome @2 NM @5 01 |
|---|
| C03 | 02 | X | FRE | @0 Lévodopa @5 04 |
|---|
| C03 | 02 | X | ENG | @0 Levodopa @5 04 |
|---|
| C03 | 02 | X | SPA | @0 Levodopa @5 04 |
|---|
| C03 | 03 | X | FRE | @0 Chimiothérapie @5 05 |
|---|
| C03 | 03 | X | ENG | @0 Chemotherapy @5 05 |
|---|
| C03 | 03 | X | SPA | @0 Quimioterapia @5 05 |
|---|
| C03 | 04 | X | FRE | @0 Antiparkinsonien @5 06 |
|---|
| C03 | 04 | X | ENG | @0 Antiparkinson agent @5 06 |
|---|
| C03 | 04 | X | SPA | @0 Antiparkinsoniano @5 06 |
|---|
| C03 | 05 | X | FRE | @0 Agoniste @5 07 |
|---|
| C03 | 05 | X | ENG | @0 Agonist @5 07 |
|---|
| C03 | 05 | X | SPA | @0 Agonista @5 07 |
|---|
| C03 | 06 | X | FRE | @0 Récepteur nicotinique @5 08 |
|---|
| C03 | 06 | X | ENG | @0 Nicotinic receptor @5 08 |
|---|
| C03 | 06 | X | SPA | @0 Receptor nicotínico @5 08 |
|---|
| C03 | 07 | X | FRE | @0 Acétylcholine @2 NK @2 FR @5 09 |
|---|
| C03 | 07 | X | ENG | @0 Acetylcholine @2 NK @2 FR @5 09 |
|---|
| C03 | 07 | X | SPA | @0 Acetilcolina @2 NK @2 FR @5 09 |
|---|
| C03 | 08 | X | FRE | @0 Neurone @5 10 |
|---|
| C03 | 08 | X | ENG | @0 Neuron @5 10 |
|---|
| C03 | 08 | X | SPA | @0 Neurona @5 10 |
|---|
| C03 | 09 | X | FRE | @0 Association médicamenteuse @5 11 |
|---|
| C03 | 09 | X | ENG | @0 Drug combination @5 11 |
|---|
| C03 | 09 | X | SPA | @0 Asociación medicamentosa @5 11 |
|---|
| C03 | 10 | X | FRE | @0 Motricité @5 13 |
|---|
| C03 | 10 | X | ENG | @0 Motricity @5 13 |
|---|
| C03 | 10 | X | SPA | @0 Motricidad @5 13 |
|---|
| C03 | 11 | X | FRE | @0 Psychométrie @5 14 |
|---|
| C03 | 11 | X | ENG | @0 Psychometrics @5 14 |
|---|
| C03 | 11 | X | SPA | @0 Psicometría @5 14 |
|---|
| C03 | 12 | X | FRE | @0 Traitement @5 17 |
|---|
| C03 | 12 | X | ENG | @0 Treatment @5 17 |
|---|
| C03 | 12 | X | GER | @0 Aufbereiten @5 17 |
|---|
| C03 | 12 | X | SPA | @0 Tratamiento @5 17 |
|---|
| C03 | 13 | X | FRE | @0 Dose efficace @5 18 |
|---|
| C03 | 13 | X | ENG | @0 Effective dose @5 18 |
|---|
| C03 | 13 | X | SPA | @0 Dosis eficaz @5 18 |
|---|
| C03 | 14 | X | FRE | @0 Relation dose réponse @5 19 |
|---|
| C03 | 14 | X | ENG | @0 Dose activity relation @5 19 |
|---|
| C03 | 14 | X | SPA | @0 Relación dosis respuesta @5 19 |
|---|
| C03 | 15 | X | FRE | @0 Singe @5 20 |
|---|
| C03 | 15 | X | ENG | @0 Monkey @5 20 |
|---|
| C03 | 15 | X | SPA | @0 Mono @5 20 |
|---|
| C03 | 16 | X | FRE | @0 Animal adulte @5 21 |
|---|
| C03 | 16 | X | ENG | @0 Adult animal @5 21 |
|---|
| C03 | 16 | X | SPA | @0 Animal adulto @5 21 |
|---|
| C03 | 17 | X | FRE | @0 Mâle @5 22 |
|---|
| C03 | 17 | X | ENG | @0 Male @5 22 |
|---|
| C03 | 17 | X | SPA | @0 Macho @5 22 |
|---|
| C03 | 18 | X | FRE | @0 SIB 1508Y @2 FR @4 INC @5 86 |
|---|
| C07 | 01 | X | FRE | @0 Primates @2 NS |
|---|
| C07 | 01 | X | ENG | @0 Primates @2 NS |
|---|
| C07 | 01 | X | SPA | @0 Primates @2 NS |
|---|
| C07 | 02 | X | FRE | @0 Mammalia @2 NS |
|---|
| C07 | 02 | X | ENG | @0 Mammalia @2 NS |
|---|
| C07 | 02 | X | SPA | @0 Mammalia @2 NS |
|---|
| C07 | 03 | X | FRE | @0 Vertebrata @2 NS |
|---|
| C07 | 03 | X | ENG | @0 Vertebrata @2 NS |
|---|
| C07 | 03 | X | SPA | @0 Vertebrata @2 NS |
|---|
| C07 | 04 | X | FRE | @0 Système nerveux pathologie @5 37 |
|---|
| C07 | 04 | X | ENG | @0 Nervous system diseases @5 37 |
|---|
| C07 | 04 | X | SPA | @0 Sistema nervioso patología @5 37 |
|---|
| C07 | 05 | X | FRE | @0 Trouble neurologique @5 38 |
|---|
| C07 | 05 | X | ENG | @0 Neurological disorder @5 38 |
|---|
| C07 | 05 | X | SPA | @0 Trastorno neurológico @5 38 |
|---|
| N21 | | | | @1 236 |
|---|
|
|---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002F65
Links to Exploration step
Pascal:98-0354366
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys</title>
<author><name sortKey="Schneider, J S" sort="Schneider, J S" uniqKey="Schneider J" first="J. S." last="Schneider">J. S. Schneider</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14><country>États-Unis</country>
</affiliation><author><name sortKey="Pope Coleman, A" sort="Pope Coleman, A" uniqKey="Pope Coleman A" first="A." last="Pope-Coleman">A. Pope-Coleman</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14><country>États-Unis</country>
</affiliation><author><name sortKey="Van Velson, M" sort="Van Velson, M" uniqKey="Van Velson M" first="M." last="Van Velson">M. Van Velson</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14><country>États-Unis</country>
</affiliation><author><name sortKey="Menzaghi, F" sort="Menzaghi, F" uniqKey="Menzaghi F" first="F." last="Menzaghi">F. Menzaghi</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>SIBIA Neurosciences, Inc</s1>
<s2>La Jolla, California</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14><country>États-Unis</country>
</affiliation><author><name sortKey="Lloyd, G K" sort="Lloyd, G K" uniqKey="Lloyd G" first="G. K." last="Lloyd">G. K. Lloyd</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>SIBIA Neurosciences, Inc</s1>
<s2>La Jolla, California</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14><country>États-Unis</country>
</affiliation><publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">98-0354366</idno>
<date when="1998">1998</date>
<idno type="stanalyst">PASCAL 98-0354366 INIST</idno>
<idno type="RBID">Pascal:98-0354366</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002F65</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003859</idno>
</publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys</title>
<author><name sortKey="Schneider, J S" sort="Schneider, J S" uniqKey="Schneider J" first="J. S." last="Schneider">J. S. Schneider</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14><country>États-Unis</country>
</affiliation><author><name sortKey="Pope Coleman, A" sort="Pope Coleman, A" uniqKey="Pope Coleman A" first="A." last="Pope-Coleman">A. Pope-Coleman</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14><country>États-Unis</country>
</affiliation><author><name sortKey="Van Velson, M" sort="Van Velson, M" uniqKey="Van Velson M" first="M." last="Van Velson">M. Van Velson</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14><country>États-Unis</country>
</affiliation><author><name sortKey="Menzaghi, F" sort="Menzaghi, F" uniqKey="Menzaghi F" first="F." last="Menzaghi">F. Menzaghi</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>SIBIA Neurosciences, Inc</s1>
<s2>La Jolla, California</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14><country>États-Unis</country>
</affiliation><author><name sortKey="Lloyd, G K" sort="Lloyd, G K" uniqKey="Lloyd G" first="G. K." last="Lloyd">G. K. Lloyd</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>SIBIA Neurosciences, Inc</s1>
<s2>La Jolla, California</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14><country>États-Unis</country>
</affiliation><series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1998">1998</date>
</imprint><seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetylcholine</term>
<term>Adult animal</term>
<term>Agonist</term>
<term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>Dose activity relation</term>
<term>Drug combination</term>
<term>Effective dose</term>
<term>Levodopa</term>
<term>Male</term>
<term>Monkey</term>
<term>Motricity</term>
<term>Neuron</term>
<term>Nicotinic receptor</term>
<term>Parkinsonism</term>
<term>Psychometrics</term>
<term>Treatment</term>
</keywords><keywords scheme="Pascal" xml:lang="fr"><term>Parkinsonisme</term>
<term>Lévodopa</term>
<term>Chimiothérapie</term>
<term>Antiparkinsonien</term>
<term>Agoniste</term>
<term>Récepteur nicotinique</term>
<term>Acétylcholine</term>
<term>Neurone</term>
<term>Association médicamenteuse</term>
<term>Motricité</term>
<term>Psychométrie</term>
<term>Traitement</term>
<term>Dose efficace</term>
<term>Relation dose réponse</term>
<term>Singe</term>
<term>Animal adulte</term>
<term>Mâle</term>
<term>SIB 1508Y</term>
</keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Singe</term>
</keywords><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01><fA03 i2="1"><s0>Mov. disord.</s0>
</fA03><fA08 i1="01" i2="1" l="ENG"><s1>Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys</s1>
</fA08><fA11 i1="01" i2="1"><s1>SCHNEIDER (J. S.)</s1>
</fA11><fA11 i1="02" i2="1"><s1>POPE-COLEMAN (A.)</s1>
</fA11><fA11 i1="03" i2="1"><s1>VAN VELSON (M.)</s1>
</fA11><fA11 i1="04" i2="1"><s1>MENZAGHI (F.)</s1>
</fA11><fA11 i1="05" i2="1"><s1>LLOYD (G. K.)</s1>
</fA11><fA14 i1="01"><s1>Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14><fA14 i1="02"><s1>SIBIA Neurosciences, Inc</s1>
<s2>La Jolla, California</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14><fA20><s1>637-642</s1>
</fA20><fA21><s1>1998</s1>
</fA21><fA23 i1="01"><s0>ENG</s0>
</fA23><fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000077139450030</s5>
</fA43><fA44><s0>0000</s0>
<s1>© 1998 INIST-CNRS. All rights reserved.</s1>
</fA44><fA45><s0>28 ref.</s0>
</fA45><fA47 i1="01" i2="1"><s0>98-0354366</s0>
</fA47><fA64 i2="1"><s0>Movement disorders</s0>
</fA64><fA66 i1="01"><s0>USA</s0>
</fA66><fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02><fC03 i1="01" i2="X" l="FRE"><s0>Parkinsonisme</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03><fC03 i1="01" i2="X" l="ENG"><s0>Parkinsonism</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03><fC03 i1="01" i2="X" l="SPA"><s0>Parkinson síndrome</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03><fC03 i1="02" i2="X" l="FRE"><s0>Lévodopa</s0>
<s5>04</s5>
</fC03><fC03 i1="02" i2="X" l="ENG"><s0>Levodopa</s0>
<s5>04</s5>
</fC03><fC03 i1="02" i2="X" l="SPA"><s0>Levodopa</s0>
<s5>04</s5>
</fC03><fC03 i1="03" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>05</s5>
</fC03><fC03 i1="03" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>05</s5>
</fC03><fC03 i1="03" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>05</s5>
</fC03><fC03 i1="04" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>06</s5>
</fC03><fC03 i1="04" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>06</s5>
</fC03><fC03 i1="04" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>06</s5>
</fC03><fC03 i1="05" i2="X" l="FRE"><s0>Agoniste</s0>
<s5>07</s5>
</fC03><fC03 i1="05" i2="X" l="ENG"><s0>Agonist</s0>
<s5>07</s5>
</fC03><fC03 i1="05" i2="X" l="SPA"><s0>Agonista</s0>
<s5>07</s5>
</fC03><fC03 i1="06" i2="X" l="FRE"><s0>Récepteur nicotinique</s0>
<s5>08</s5>
</fC03><fC03 i1="06" i2="X" l="ENG"><s0>Nicotinic receptor</s0>
<s5>08</s5>
</fC03><fC03 i1="06" i2="X" l="SPA"><s0>Receptor nicotínico</s0>
<s5>08</s5>
</fC03><fC03 i1="07" i2="X" l="FRE"><s0>Acétylcholine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03><fC03 i1="07" i2="X" l="ENG"><s0>Acetylcholine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03><fC03 i1="07" i2="X" l="SPA"><s0>Acetilcolina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03><fC03 i1="08" i2="X" l="FRE"><s0>Neurone</s0>
<s5>10</s5>
</fC03><fC03 i1="08" i2="X" l="ENG"><s0>Neuron</s0>
<s5>10</s5>
</fC03><fC03 i1="08" i2="X" l="SPA"><s0>Neurona</s0>
<s5>10</s5>
</fC03><fC03 i1="09" i2="X" l="FRE"><s0>Association médicamenteuse</s0>
<s5>11</s5>
</fC03><fC03 i1="09" i2="X" l="ENG"><s0>Drug combination</s0>
<s5>11</s5>
</fC03><fC03 i1="09" i2="X" l="SPA"><s0>Asociación medicamentosa</s0>
<s5>11</s5>
</fC03><fC03 i1="10" i2="X" l="FRE"><s0>Motricité</s0>
<s5>13</s5>
</fC03><fC03 i1="10" i2="X" l="ENG"><s0>Motricity</s0>
<s5>13</s5>
</fC03><fC03 i1="10" i2="X" l="SPA"><s0>Motricidad</s0>
<s5>13</s5>
</fC03><fC03 i1="11" i2="X" l="FRE"><s0>Psychométrie</s0>
<s5>14</s5>
</fC03><fC03 i1="11" i2="X" l="ENG"><s0>Psychometrics</s0>
<s5>14</s5>
</fC03><fC03 i1="11" i2="X" l="SPA"><s0>Psicometría</s0>
<s5>14</s5>
</fC03><fC03 i1="12" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03><fC03 i1="12" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03><fC03 i1="12" i2="X" l="GER"><s0>Aufbereiten</s0>
<s5>17</s5>
</fC03><fC03 i1="12" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03><fC03 i1="13" i2="X" l="FRE"><s0>Dose efficace</s0>
<s5>18</s5>
</fC03><fC03 i1="13" i2="X" l="ENG"><s0>Effective dose</s0>
<s5>18</s5>
</fC03><fC03 i1="13" i2="X" l="SPA"><s0>Dosis eficaz</s0>
<s5>18</s5>
</fC03><fC03 i1="14" i2="X" l="FRE"><s0>Relation dose réponse</s0>
<s5>19</s5>
</fC03><fC03 i1="14" i2="X" l="ENG"><s0>Dose activity relation</s0>
<s5>19</s5>
</fC03><fC03 i1="14" i2="X" l="SPA"><s0>Relación dosis respuesta</s0>
<s5>19</s5>
</fC03><fC03 i1="15" i2="X" l="FRE"><s0>Singe</s0>
<s5>20</s5>
</fC03><fC03 i1="15" i2="X" l="ENG"><s0>Monkey</s0>
<s5>20</s5>
</fC03><fC03 i1="15" i2="X" l="SPA"><s0>Mono</s0>
<s5>20</s5>
</fC03><fC03 i1="16" i2="X" l="FRE"><s0>Animal adulte</s0>
<s5>21</s5>
</fC03><fC03 i1="16" i2="X" l="ENG"><s0>Adult animal</s0>
<s5>21</s5>
</fC03><fC03 i1="16" i2="X" l="SPA"><s0>Animal adulto</s0>
<s5>21</s5>
</fC03><fC03 i1="17" i2="X" l="FRE"><s0>Mâle</s0>
<s5>22</s5>
</fC03><fC03 i1="17" i2="X" l="ENG"><s0>Male</s0>
<s5>22</s5>
</fC03><fC03 i1="17" i2="X" l="SPA"><s0>Macho</s0>
<s5>22</s5>
</fC03><fC03 i1="18" i2="X" l="FRE"><s0>SIB 1508Y</s0>
<s2>FR</s2>
<s4>INC</s4>
<s5>86</s5>
</fC03><fC07 i1="01" i2="X" l="FRE"><s0>Primates</s0>
<s2>NS</s2>
</fC07><fC07 i1="01" i2="X" l="ENG"><s0>Primates</s0>
<s2>NS</s2>
</fC07><fC07 i1="01" i2="X" l="SPA"><s0>Primates</s0>
<s2>NS</s2>
</fC07><fC07 i1="02" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07><fC07 i1="02" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07><fC07 i1="02" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07><fC07 i1="03" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07><fC07 i1="03" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07><fC07 i1="03" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07><fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07><fC07 i1="04" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07><fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07><fC07 i1="05" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>38</s5>
</fC07><fC07 i1="05" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>38</s5>
</fC07><fC07 i1="05" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>38</s5>
</fC07><fN21><s1>236</s1>
</fN21>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003859 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 003859 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:98-0354366
|texte= Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys
}}
| This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024 |  |
